Correlates of Anti-EBV EBNA1 IgA Positivity Among Unaffected Relatives from Nasopharyngeal Carcinoma Multiplex Families

Overview

Journal Br J Cancer

Specialty Oncology

Date 2011 Nov 19

PMID 22095229

Citations 2

Authors

C M Chang

K J Yu

W L Hsu

J M Major

J Y Chen

P J Lou

M Y Liu

S R Diehl

A M Goldstein

C J Chen

A Hildesheim

Affiliations

Soon will be listed here.

Abstract

Background: To determine whether non-viral nasopharyngeal carcinoma (NPC) risk factors might be associated with (and mediated through) Epstein-Barr virus (EBV) serological responses linked to NPC risk, we evaluated predictors of risk of anti-EBNA1 IgA seropositivity and other markers among unaffected relatives from a large NPC family study in Taiwan.

Methods: Multivariate logistic regression conditioned on family was used to examine the associations between sociodemographic, dietary, lifestyle, and occupational variables and risk of anti-EBV EBNA1 IgA positivity, anti-VCA IgA, and anti-DNase positivity.

Results: Among 2393 unaffected relatives from 319 multiplex families, 1180 (49.3%) were anti-EBV EBNA1 IgA seropositive. None of the associations with anti-EBNA1 IgA were statistically significant, except for being 31-50 years of age (vs <30, adjusted ORs 0.51-0.57). For one or more EBV serological markers, there were suggestive associations for older age, GuangDong firm salted fish, betel use, current alcohol use, and male gender.

Conclusion: Overall, we found little evidence to suggest that non-viral NPC risk factors significantly alter EBV serological patterns, suggesting that non-viral NPC risk factors act through pathways independent of EBV serological responses.

Citing Articles

A Distinct Anti-EBV DNase Profile in Patients with Undifferentiated Nasopharyngeal Carcinoma Compared to Classical Antigens.

Melouli H, Khenchouche A, Taibi-Zidouni F, Salma D, Aoudia N, Djennaoui D Viruses. 2023; 15(11).

PMID: 38005835 PMC: 10675439. DOI: 10.3390/v15112158.

Predictors of Epstein-Barr virus serostatus and implications for vaccine policy: A systematic review of the literature.

Winter J, Jackson C, Lewis J, Taylor G, Thomas O, Stagg H J Glob Health. 2020; 10(1):010404.

PMID: 32257152 PMC: 7125428. DOI: 10.7189/jogh.10.010404.

References

Ng W, Choi C, Lee M, Law L, Yau T, Lee A . Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. Fam Cancer. 2009; 9(2):221-8. DOI: 10.1007/s10689-009-9296-y. View

. Betel-quid and areca-nut chewing and some areca-nut derived nitrosamines. IARC Monogr Eval Carcinog Risks Hum. 2005; 85:1-334. PMC: 4781453. View

Pickard A, Chen C, Diehl S, Liu M, Cheng Y, Hsu W . Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. Int J Cancer. 2004; 111(1):117-23. DOI: 10.1002/ijc.20222. View

Zeng Y, Zhang L, Wu Y, Huang Y, Huang N, Li J . Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer. 1985; 36(5):545-7. DOI: 10.1002/ijc.2910360505. View

Zeng Y, Zhong J, Li L, Wang P, Tang H, Ma Y . Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, China. Intervirology. 1983; 20(4):190-4. DOI: 10.1159/000149391. View

Chang E, Adami H . The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006; 15(10):1765-77. DOI: 10.1158/1055-9965.EPI-06-0353. View

Ji M, Wang D, Yu Y, Guo Y, Liang J, Cheng W . Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer. 2007; 96(4):623-30. PMC: 2360049. DOI: 10.1038/sj.bjc.6603609. View

Hsu W, Chen J, Chien Y, Liu M, You S, Hsu M . Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622 males without family history in Taiwan. Cancer Epidemiol Biomarkers Prev. 2009; 18(4):1218-26. DOI: 10.1158/1055-9965.EPI-08-1175. View

Yang X, Diehl S, Pfeiffer R, Chen C, Hsu W, Dosemeci M . Evaluation of risk factors for nasopharyngeal carcinoma in high-risk nasopharyngeal carcinoma families in Taiwan. Cancer Epidemiol Biomarkers Prev. 2005; 14(4):900-5. DOI: 10.1158/1055-9965.EPI-04-0680. View

10.

Pfeiffer R, Hildesheim A, Gail M, Pee D, Chen C, Goldstein A . Robustness of inference on measured covariates to misspecification of genetic random effects in family studies. Genet Epidemiol. 2003; 24(1):14-23. DOI: 10.1002/gepi.10191. View

11.

Chien Y, Chen J, Liu M, Yang H, Hsu M, Chen C . Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 2002; 345(26):1877-82. DOI: 10.1056/NEJMoa011610. View

12.

Agarwal S, Busse P . Innate and adaptive immunosenescence. Ann Allergy Asthma Immunol. 2010; 104(3):183-90. DOI: 10.1016/j.anai.2009.11.009. View

13.

Chang M, Chiang C, Lin C, Lee J, Hahn L, Jeng J . Cell-mediated immunity and head and neck cancer: with special emphasis on betel quid chewing habit. Oral Oncol. 2005; 41(8):757-75. DOI: 10.1016/j.oraloncology.2005.01.007. View

14.

Jeng J, Ho Y, Chan C, Wang Y, Hahn L, Lei D . Areca nut extract up-regulates prostaglandin production, cyclooxygenase-2 mRNA and protein expression of human oral keratinocytes. Carcinogenesis. 2000; 21(7):1365-70. View

15.

Shao Y, Poirier S, Ohshima H, Malaveille C, Zeng Y, de The G . Epstein-Barr virus activation in Raji cells by extracts of preserved food from high risk areas for nasopharyngeal carcinoma. Carcinogenesis. 1988; 9(8):1455-7. DOI: 10.1093/carcin/9.8.1455. View

16.

Yu K, Hsu W, Chiang C, Cheng Y, Pfeiffer R, Diehl S . Cancer patterns in nasopharyngeal carcinoma multiplex families in Taiwan. Int J Cancer. 2008; 124(7):1622-5. PMC: 2796215. DOI: 10.1002/ijc.24051. View

17.

Jeng J, Wang Y, Chiang B, Lee P, Chan C, Ho Y . Roles of keratinocyte inflammation in oral cancer: regulating the prostaglandin E2, interleukin-6 and TNF-alpha production of oral epithelial cells by areca nut extract and arecoline. Carcinogenesis. 2003; 24(8):1301-15. DOI: 10.1093/carcin/bgg083. View

18.

Yu K, Hsu W, Pfeiffer R, Chiang C, Wang C, Lou P . Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families. Clin Cancer Res. 2011; 17(7):1906-14. PMC: 3268357. DOI: 10.1158/1078-0432.CCR-10-1681. View